吡咯烷-1-丁酸盐酸盐 | 49637-21-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 吡咯烷-1-丁酸盐酸盐
• 英文名称: 4-(pyrrolidin-1-yl)butanoic acid hydrochloride
• 英文别名: 4-(pyrrolidin-1-yl)butyric acid hydrochloride；4-pyrrolidin-1-ylbutanoic acid;hydrochloride
• CAS: 49637-21-0
• 化学式: C₈H₁₅NO₂*ClH
• mdl: MFCD06801275
• 分子量: 193.674
• InChiKey: ZEWPJQOFVHRHKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.13
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  雷公藤甲素 、 吡咯烷-1-丁酸盐酸盐 在 4-二甲氨基吡啶 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 14-((4'-N-pyrrolidino)butyrate)hydrochloride salt ester of triptolide
  参考文献：
  名称：

  Treatment of acute myeloid leukemia

  摘要：

  本发明涉及使用三尖杉酯衍生物、三倍杉酯、16-羟基三尖杉酯、其药用盐或其组合物，用于制备包含三尖杉酯前药的药物，用于治疗急性髓样白血病。

  公开号：

  EP1946758A1
• 作为产物：
  描述：

  吡咯烷-1-丁酸 在 盐酸 作用下， 以 水 为溶剂， 生成 吡咯烷-1-丁酸盐酸盐
  参考文献：
  名称：

  Oxidant-Free Conversion of Cyclic Amines to Lactams and H₂ Using Water As the Oxygen Atom Source

  摘要：

  Direct conversion of cyclic amines to lactams utilizing water as the only reagent is catalyzed by pincer complex 2. In contrast to previously known methods of amine-to-amide conversion, this reaction occurs in the absence of oxidants and is accompanied by liberation of H-2, with water serving as a source of oxygen atom. Formation of a cyclic hemiaminal intermediate plays a key role in enabling such reactivity. This represents an unprecedented, conceptually new type of amide formation reaction directly from amines and water under oxidant-free conditions.

  DOI：

  10.1021/ja500026m

文献信息

• Synthesis and Biological Evaluation of NK1 Antagonists Derived from L-Tryptophan
  作者：Angus M. MacLeod、Margaret A. Cascieri、Kevin J. Merchant、Sharon Sadowski、Sarah Hardwicke、Richard T. Lewis、D. Euan MacIntyre、Joseph M. Metzger、Tung Ming Fong

  DOI：10.1021/jm00006a012

  日期：1995.3

  intermediate amino ketone 15 was developed which allows its preparation on a large scale. From this intermediate a range of amine-containing acylamino derivatives were prepared with affinity optimized in the morpholinylbutyramide 161 which has an IC50 of 0.17 nM at the human NK1 receptor. In addition to improving affinity, the amino group also provided aqueous solubility for a number of these derivatives. When

  N-乙酰基-L-色氨酸苄酯的3,5-双（三氟甲基）苄基酯（3）来源于筛选铅N-乙基-L-色氨酸苄酯，已被用作鉴定高-亲和性物质P受体拮抗剂具有改善的体内活性。将酯部分改变为酰胺或醚会导致结合亲和力的显着损失，但是转化为酮可提供与当量酯相当的亲和力的化合物。关键中间体氨基酮15的同手性合成得以开发，可以大规模制备。从该中间体中制备了一系列含胺的酰氨基衍生物，并在吗啉基丁酰胺161中对亲和力进行了优化，该衍生物对人NK1受体的IC50为0.17 nM。除了改善亲和力 氨基还为许多这些衍生物提供了水溶性。在体内进行测试时，发现奎尼丁衍生物L-737,488（16i）是豚鼠中P物质诱导的皮肤外渗的口服活性抑制剂（ID50 = 1.8 mg / kg）。
• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• NANOMATERIALS
  申请人：Guide Therapeutics, Inc.

  公开号：US20210169804A1

  公开（公告）日：2021-06-10

  Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

  描述了用于传递核酸的脂质纳米粒子组合物。脂质纳米粒子可能包含作为组合物的一部分的构象受限的可离子化脂质。这些组合物可能允许传递货物而无需靶向配体。
• Heterocyclic esters of benzopyrans
  申请人：Sharps Associates

  公开号：US03941782A1

  公开（公告）日：1976-03-02

  This invention relates to novel esters of benzopyrans represented by the formulae ##SPC1## Wherein R and R' are hydrogen or C.sub.1 -C.sub.6 alkyl and when alkyl are on the same or different carbons; R.sub.1 is C.sub.1 -C.sub.6 alkyl; R.sub.2 is C.sub.1 -C.sub.20 alkyl, lowercycloalkyloweralkyl or lowercycloalkyl; n is an integer from 3 to 7, and particularly 3 to 5; Y is a straight or branched chain C.sub.1 -C.sub.8 alkylene; and R.sub.3 is ##EQU1## WHEREIN A IS AN INTEGER FROM 1 TO 4, B IS AN INTEGER FROM 1 TO 4, X is O,S, CH.sub.2 or NR.sub.4 and R.sub.4 is hydrogen C.sub.1 -C.sub.6 alkyl, and R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and the acid addition salts thereof. The compounds exhibit analgesic and central nervous system activity.

  这项发明涉及由以下式表示的新型苯并吡喁酯 ##SPC1## 其中R和R'为氢或C.sub.1 -C.sub.6烷基，当烷基位于相同或不同的碳上时；R.sub.1为C.sub.1 -C.sub.6烷基；R.sub.2为C.sub.1 -C.sub.20烷基，较低的环烷烃较低的烷基或较低的环烷烃；n为3到7的整数，特别是3到5；Y为直链或支链C.sub.1 -C.sub.8亚烷基；R.sub.3为##EQU1## 其中A为1到4的整数，B为1到4的整数，X为O、S、CH.sub.2或NR.sub.4，R.sub.4为氢C.sub.1 -C.sub.6烷基，R.sub.5为氢或C.sub.1 -C.sub.6烷基；以及它们的酸盐。这些化合物表现出镇痛和中枢神经系统活性。
• FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1396488A1

  公开（公告）日：2004-03-10

  The fused heterocyclic compound of the present invention, which is represented by the formula (I): wherein each symbol is as defined in the specification, an optically active form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a water adduct thereof show poly(ADP-ribose) synthase inhibitory action and are useful as therapeutic drugs for cerebral infarction.

  本发明的融合杂环化合物，其化学式表示为（I）：其中每个符号如规范中定义，其光学活性形式，其药学上可接受的盐，其水合物和水加合物显示聚(ADP-核糖)合酶抑制作用，并可用作治疗脑梗死的药物。